Abstract: The present invention relates to an EBV antigen specific T-cell receptor and the use thereof. Specifically, the present invention provides T cells specific for LMP1 of EBV using a T-cell receptor which is highly specific for specific epitopes derived from an EBV antigen, LMP1. In addition, the EBV antigen specific T-cell can be used in the prevention or treatment of EBV-associated diseases.
Type:
Grant
Filed:
May 8, 2018
Date of Patent:
April 9, 2019
Assignee:
The Catholic Unviersity of Korea Industry-Academic Cooperation Foundation